Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

Other equities research analysts have also issued reports about the stock. JMP Securities increased their price objective on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 11th. Robert W. Baird increased their price objective on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a report on Tuesday, August 8th. Royal Bank Of Canada started coverage on shares of Enanta Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating for the company. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $38.00 price objective (up from $32.00) on shares of Enanta Pharmaceuticals in a report on Wednesday, August 9th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $42.33.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 0.32% during midday trading on Tuesday, reaching $48.38. 118,850 shares of the company’s stock traded hands. The firm’s market capitalization is $923.57 million. Enanta Pharmaceuticals has a one year low of $22.17 and a one year high of $48.80. The stock’s 50-day moving average price is $43.86 and its 200 day moving average price is $36.40.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The business had revenue of $7.51 million during the quarter, compared to analyst estimates of $8.08 million. During the same period last year, the firm posted ($0.06) EPS. The company’s revenue was down 46.3% on a year-over-year basis. On average, equities research analysts expect that Enanta Pharmaceuticals will post $1.14 earnings per share for the current fiscal year.

WARNING: “Enanta Pharmaceuticals, Inc. (ENTA) Raised to “Hold” at Zacks Investment Research” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/10/enanta-pharmaceuticals-inc-enta-raised-to-hold-at-zacks-investment-research.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Texas Permanent School Fund boosted its position in shares of Enanta Pharmaceuticals by 0.8% during the 2nd quarter. Texas Permanent School Fund now owns 10,146 shares of the biotechnology company’s stock valued at $365,000 after acquiring an additional 85 shares during the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Enanta Pharmaceuticals by 3.5% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 110 shares during the last quarter. Eqis Capital Management Inc. boosted its position in shares of Enanta Pharmaceuticals by 0.6% during the 2nd quarter. Eqis Capital Management Inc. now owns 31,565 shares of the biotechnology company’s stock valued at $1,136,000 after acquiring an additional 173 shares during the last quarter. Mason Street Advisors LLC boosted its position in shares of Enanta Pharmaceuticals by 7.0% during the 1st quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 212 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Enanta Pharmaceuticals by 5.8% during the 2nd quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 237 shares during the last quarter. Hedge funds and other institutional investors own 66.06% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.